// App-Quantinova.ai

: Safety of riociguat for the treatment of pulmonary hypertension: Data from the EXPERT registry

Researchers

Presenter

  • Henning Gall

Principal Investigators

  • Marc Humbert

  • Grald Simonneau

  • Ekkehard Grnig

  • Hans Klose

  • Michael Halank

  • David Langleben

  • Lisa M. Mielniczuk

  • Jean-Luc Vachiry

  • Hubert Wirtz

  • Tobias Lange

  • Pilar Escribano

  • Douglas S Helmersen

  • Joanna Pepke-Zaba

  • Iraklis Tsangaris

  • Anco Boonstra

  • Joan Albert Barber

  • Repke J. Snijder

  • Regina Mascherbauer

  • Marion Delcroix

  • Miguel Angel Gomez Snchez

  • Jens Klotsche

  • Christian Meier

  • David Pittrow

  • Marius M. Hoeper

Medical Centers

  • University of Giessen and Marburg Lung Center member of the German Center of Lung Research DZL, Giessen, Germany

  • Université Paris-Sud, Le Kremlin-Bicêtre, Service de Pneumologie, Centre de Référence de l’Hypertension Pulmonaire Sévère, DHU Thorax Innovation, Hôpital Bicêtre, Le Kremlin-Bicêtre,, Paris,, France

  • Centre for Pulmonary Hypertension at Thoraxklinik Heidelberg, Heidelberg, Germany,

  • Pediatric Nephrology, University Medical Center Hamburg-Eppendorf, Hamburg, Germany

  • Medical Clinic I, Department of Pneumology, University Hospital Carl Gustav Carus, Dresden, Germany,

  • Jewish General Hospital/ McGill Univeristy, Montreal, QC, Canada

  • Division of Cardiology, Department of Medicine, University of Ottawa Heart Institute, Ottawa, ON, Canada,

  • Departement de Cardiologie, Cliniques Universitaires de Bruxelles, Hopital Erasme, Brussels, Belgium

  • Department of Nuclear Medicine, University of Leipzig, Leipzig, Germany

  • Department of Internal Medicine II, Division of Pneumology, University Medical Center, Regensburg, Germany,

  • Department of Cardiology, Hospital 12 de Octubre, Madrid, Spain,

  • Alberta Health Services, University of Calgary, Calgary, AB, Canada,

  • Pulmonary Vascular Disease Unit, Papworth Hospital, Cambridge, United Kingdom

  • Second Department of Critical Care, University Hospital Attikon, Athens, Germany,

  • VU Medisch Centrum,, Amsterdam,, Netherlands

  • Hospital Clínic-Institut d'Investigacions Biomèdiques August Pi i Sunyer and University of Barcelona, Barcelona, Spain,

  • Department of Pulmonology, St Antonius Ziekenhuis, Nieuwegein, Netherlands,

  • Servicestelle für klinische Studien, Krankenhaus der Elisabethinen Linz GmbH, Linz, Austria,

  • Department of Pulmonology, Katholieke Universiteit,, Leuven,, Belgium

  • Hospital General Nuestra Señora del Prado, Talavera de la Reina,, CIBERES,, Spain

  • Global Medical Affairs, Bayer AG,, Berlin,, Germany

  • Institute for Clinical Pharmacology, Medical Faculty, Technical University, Dresden, Germany

  • Clinic for Respiratory Medicine, Hannover Medical School, Member of the German Center for Lung Research (DZL), Hannover, Germany

Locations

  • Germany

  • France

  • Canada

  • Belgium

  • Spain

  • United Kingdom

  • Greece

  • Netherlands

  • Austria

Companies

  • N/A

Study Components

Therapeutic Area

  • Cardiovascular (CVS)

Disease

  • Pulmonary arterial hypertension

Biomarkers

  • N/A

Drug/Treatment

  • Riociguat

Outcome

  • N/A

Study Design

  • Non Interventional

  • Multinational

  • Multicenteric

  • Prospective

Phase

  • NA

Study Id's

  • NCT02092818

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved